Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 3379
116th Congress(2019-2020)
PRICED Act
Introduced
Introduced
Introduced in House on Jun 20, 2019
Overview
Text
Introduced in House 
Jun 20, 2019
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Jun 20, 2019)
Jun 20, 2019
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 3379 (Introduced-in-House)


116th CONGRESS
1st Session
H. R. 3379


To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.

IN THE HOUSE OF REPRESENTATIVES

June 20, 2019

Ms. Schakowsky (for herself, Mr. Westerman, Ms. DeLauro, Ms. Craig, Mr. Doggett, Mr. Krishnamoorthi, Mr. Khanna, Mr. Cicilline, Mr. Pocan, Mr. Rush, Mr. Levin of Michigan, Mr. Morelle, Ms. Jayapal, Ms. Tlaib, Ms. Kaptur, Mr. Welch, and Mr. García of Illinois) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Price Relief, Innovation, and Competition for Essential Drugs Act” or the “PRICED Act”.

SEC. 2. Exclusivity period for brand name biological products.

(a) In general.—Section 351(k)(7)(A) of the Public Health Service Act (42 U.S.C. 262(k)(7)(A)) is amended by striking “12 years” and inserting “5 years”.

(b) Conforming changes.—Paragraphs (2)(A) and (3)(A) of section 351(m) of the Public Health Service Act (42 U.S.C. 262(m)) is amended by striking “12 years” each place it appears and inserting “5 years”.

(c) Applicability.—This Act and the amendments made by this Act apply only with respect to a biological product for which the reference product (as such term is used in section 351 of the Public Health Service Act (42 U.S.C. 262)) is licensed under subsection (a) of such section on or after the date of enactment of this Act.